upadacitinib
abbvie
[' upa ', ' uc ', 'upadacitinib', 'ibd']
#brianfeagan benefits of high versus low dose upadacitinib as maintenance treatment in uc (p-iii maintenance trial). #uegw2022 #ibd -&gt; less severe disease and longer clinical remission for 30 vs. 15 mg upa -&gt; "therapeutic index" may drive future treatment decision 
Professor of Medicine, Gastroenterologist, specializing in the care of patients with IBD.
National representative of Germany @ https://t.co/Qr0PthTmU8 ex @Y_ECCO_IBD chair